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Abstract Here, we developed a binary vector system that in-
troduces a synthetic SUMO-1 conjugation pathway into Esche-
richia coli and demonstrated that large amounts of sumoylated
Ran GTPase activating protein 1 C-terminal region (Ran-
GAP1-C2), Ran binding protein 2 internal repeat domain, p53
and promyelocytic leukemia were e⁄ciently produced. The su-
moylated recombinant RanGAP1-C2 appeared to retain the in
vivo properties, since it was speci¢cally sumoylated at lysine 517
as expected from in vivo studies. Our ¢ndings indicate the es-
tablishment of a biosynthetic route for producing large amounts
of sumoylated recombinant proteins that will open up new ave-
nues for studying the biochemical and structural aspects of the
SUMO-1 modi¢cation pathway.
0 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
With the help of the E1-activating enzyme composed of a
Aos1/Uba2 heterodimer and the E2-conjugating enzyme Ubc9
(ubiquitin conjugating enzyme 9), SUMO-1 (small ubiquitin-
related modi¢er-1) becomes covalently attached to acceptor
proteins [1^5]. This posttranslational modi¢cation is referred
to as ‘sumoylation’. Sumoylation is likely to constitute a new
and important mechanism through which the structure and/or
function of target proteins are regulated. However, little is
known about the biochemical and structural di¡erences be-
tween non-modi¢ed and sumoylated target proteins. This is
due, in part, to the di⁄culties of producing large amounts of
recombinant sumoylated proteins of interest in bacteria such
as Escherichia coli.
Here, we describe the establishment of a binary vector
system that allows simultaneous expression of SUMO-E1,
SUMO-E2, SUMO-1 and an acceptor protein, leading to e⁄-
cient sumoylation of the protein of interest in E. coli. Our
data indicate that the bacterial expression/modi¢cation system
is a powerful tool for the rational design and large-scale syn-
thesis of a wide variety of sumoylated proteins, which might
be invaluable for biochemical and structural studies of the
SUMO-1 conjugation and de-conjugation pathways.
2. Materials and methods
2.1. DNA constructs
Mouse Aos1 and Uba2 were ampli¢ed by polymerase chain reac-
tion (PCR) [5] using the following oligonucleotides: 5P-AGGGATC
CCCATGGTAGAGAAGGAGGAGGCTGGC-3P (coding strand of
Aos1), 5P-AGGAATTCTCACTGGGGACCAAGGCACTC-3P (anti-
coding strand of Aos1), 5P-AGGAATTCCCATGGCACTGTCGC-
GGGGGTTG-3P (coding strand of Uba2), and 5P-AGTCTAGAT-
CAGTCTAACGCTATGACGTCA-3P (anticoding strand of Uba2).
The underlined sequences represent BamHI, EcoRI, and XbaI sites,
respectively. The ampli¢ed Aos1 and Uba2 fragments were introduced
into pGEX (Amersham-Pharmacia) and pET (Novagen) vectors, re-
sulting in the formation of pGEX-Aos1, pGEX-Uba2, pET-(His)6-
Aos1, and pET-(His)6-Uba2, respectively. To prepare an Aos1-
Uba2 chimeric construct, the ampli¢ed fragments of Aos1 and
Uba2 were digested with BamHI+EcoRI and EcoRI+XbaI, respec-
tively, and inserted into a BamHI+XbaI-digested pGEX-KG vector.
The resultant plasmid, pGEX-AU, encoded a glutathione S-transfer-
ase (GST)-Aos1-Uba2 fusion protein. The expression plasmids of
Xenopus Ubc9, Ran GTPase activating protein 1 C-terminal region
(RanGAP1-C2), human SUMO-1, Ran binding protein 2 internal
repeat domain (RanBP2-IR), p53 and promyelocytic leukemia
(PML) were described previously [5^8].
2.2. Construction of the binary vector system
The Ubc9-coding region fused to the T7 promoter was prepared by
PCR using pT7-Ubc9 as a template. The fragment was digested with
NheI and inserted into the XbaI site of pGEX-AU, resulting in the
formation of the p-I plasmid that produces E1 and E2 enzymes under
the control of Tac and T7 promoters, respectively. To create the p-II
plasmid, a SUMO-1 fragment was ampli¢ed by PCR and inserted into
the NdeI-HindIII site of pACYC-T7 vector [9], resulting in the for-
mation of pACYC-SUMO-1. The RanGAP1-C2-coding region fused
to (His)6 and T7 tag and the T7 promoter was ampli¢ed by PCR and
inserted into the BglII site of pACYC-SUMO-1. The resulting plas-
mid, designated p-II(SUMO-1+RanGAP1-C2), generates (His)6-T7-
tagged RanGAP1-C2 and SUMO-1 under the control of T7 pro-
moters. The RanGAP1-C2 gene in the p-II plasmid can be replaced
by any protein-coding sequence of interest for sumoylation in E. coli.
Bacteria harboring both the p-I and p-II plasmids were selected by
Luria^Bertani medium containing 100 mg/l ampicillin and 50 mg/l
chloramphenicol.
2.3. Expression and puri¢cation of recombinant proteins
The pGEX, pET, and pACYC expression plasmids were introduced
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into E. coli BL21(DE3) and expression of the recombinant proteins
was induced with 0.2 mM isopropyl-L-D-thiogalactose (IPTG) at
25‡C. Puri¢cation of GST fusion proteins and (His)6 fusion proteins
was carried out as described previously [5,6,8]. The puri¢ed GST
fusion proteins were incubated with thrombin to remove the GST
moiety.
2.4. In vitro sumoylation assay
To prepare biotinylated SUMO-1, approximately 2.5 mg of GST-
SUMO-1 was incubated with 1.2 mg of EZ-Link1PEO-maleimide-
activated biotin (Pierce) followed by thrombin cleavage of the GST
moiety. A typical in vitro sumoylation reaction was carried out in the
reaction bu¡er containing 50 mM Tris^HCl, pH 7.6, 50 mM NaCl,
2 mM MgCl2, 0.1 mM dithiothreitol (DTT), 5 mM ATP.
3. Results
3.1. AU activates SUMO-1 in vitro
Ubiquitin E1 (Uba1) enzyme is a single subunit protein.
Several E1 enzymes for ubiquitin-like proteins, including
SUMO-E1 (Aos1/Uba2 heterodimer), consist of two subunits
that resemble the N- and C-terminal halves of ubiquitin E1
[3^5]. But the reason for this remains unclear. To mimic ubiq-
uitin E1 and investigate whether a single peptide version of
SUMO-E1 mediates the sumoylation reaction, we ¢rst de-
signed a fused Aos1 and Uba2 subunit, designated AU, and
prepared a bacterial expression plasmid followed by produc-
tion of the recombinant GST-AU protein (Fig. 1A,B). We
then tested whether GST-AU conferred the expected enzy-
matic activity in vitro. As shown in Fig. 1C, GST-AU formed
a DTT-sensitive adduct with SUMO-1 and transferred
SUMO-1 to Ubc9 in the presence of ATP. It was also dem-
onstrated that GST-AU and Ubc9 together were able to su-
moylate the C-terminal region of RanGAP1 (RanGAP1-C2
wt) in vitro (Fig. 1D). We further showed that SUMO-1
wild type (wt), but not SUMO-1G96 mutant, was conjugated
to RanGAP1-C2 wt, and found that neither SUMO-1 nor
SUMO-1G96 was conjugated to RanGAP1-C2 K517R mu-
tant, in which the SUMO-1 acceptor lysine residue is mutated
to arginine (Fig. 1D). These data indicate that the chimeric
AU has the ability to activate the SUMO-1 conjugation path-
way and catalyzes sumoylation with a similar speci¢city to the
authentic Aos1/Uba2 heterodimer.
3.2. The recombinant AU is less active than Aos1/Una2
heterodimer
It should be noted that the assays shown in Fig. 1C,D are
all endpoint, not rate, determinations and might not represent
a meaningful test of enzymatic e⁄ciency. Additionally, the E1
proteins used in these experiments were GST and (His)6 fu-
sion proteins that may not be optimally active. Therefore, we
removed the GST and (His)6 moieties from the fusion pro-
teins (Fig. 2A) and compared AU with the Aos1/Uba2 hetero-
dimer for its sumoylation e⁄ciency of RanGAP1-C2, both
by a time course and by titrating the amount needed. As
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Fig. 1. The recombinant GST-AU protein functions as a SUMO-E1
enzyme. A: Schematic representation of mouse Uba1, Aos1, Uba2
and AU proteins [3,4]. B: Puri¢cation of recombinant GST-AU
protein. Recombinant (His)6-Aos1 (arrow), GST-Uba2 (arrowhead)
and GST-AU (line) proteins were expressed. The puri¢ed proteins
(0.2 Wg/lane) were separated in a 12% sodium dodecyl sulfate^poly-
acrylamide gel electrophoresis (SDS^PAGE) gel and stained with
Coomassie blue. Protein size markers are indicated on the left. C:
GST-AU activates SUMO-1. 0.1 Wg of biotinylated SUMO-1 was
incubated with 0.5 Wg of puri¢ed (His)6-Aos1/GST-Uba2 or GST-
AU, as indicated, in the presence of 5 mM ATP at 37‡C for 20
min. The reaction mixtures were subjected to 12% SDS^PAGE in
the absence (left panel) or presence (right panel) of DTT followed
by immunoblotting analysis using avidin-conjugated horseradish per-
oxidase. Arrows indicate the position of free biotinylated SUMO-1.
The arrowhead represents the position of SUMO-1-Ubc9. The dot
shows the position of SUMO-1-GST-AU. The circle indicates the
position of SUMO-1-GST-Uba2. D: SUMO-1 is conjugated to
RanGAP1-C2 in vitro by GST-AU. The conjugation reactions were
performed with 5 mM ATP, 0.1 Wg of biotinylated wild-type
SUMO-1, 0.1 Wg of (His)6-Ubc9 and 0.5 Wg of GST-AU (lane 1).
To demonstrate the speci¢city of the reaction, inactive forms of
biotinylated SUMO-1 (SUMO-1G96: 0.1 Wg) and a RanGAP1-
C2K517R mutant (RanGAP1-C2KR: 0.1 Wg) were included in simi-
lar reactions (lanes 2 and 3). Reaction mixtures were fractionated
by 12% SDS^PAGE followed by immunoblotting analyses using an
anti-T7 antibody to detect RanGAP1-C2 (lanes 1^3, left panel) or
an anti-SUMO-1 antibody (lanes 1^3, right panel). The arrow indi-
cates the position of free biotinylated SUMO-1. The arrowhead
shows the position of RanGAP1-C2. The thin line represents the
position of sumoylated RanGAP1-C2.
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shown in Fig. 2B,C, the Aos1/Uba2 heterodimer approxi-
mately 10-fold more e⁄ciently sumoylated RanGAP1-C2
than AU, suggesting that AU may in fact be less active
than the Aos1/Uba2 heterodimer. However, it should be
noted that AU overcame the sumoylation rate when a 10-
fold excess amount of AU was added to the reaction, indicat-
ing that AU e⁄ciently mediates sumoylation if it is over-pro-
duced (Fig. 2C).
Collectively, the results indicate that AU functions as a
SUMO-E1 enzyme and imply that the heterodimeric structure
of the SUMO-E1 enzyme is not totally essential for the enzy-
matic activity per se. Since the linear fusion of Aos1 and Uba2
would not only negate the heterodimerization process of the
two proteins but also eliminate the possibility of unbalanced
production of the two proteins, we predicted that AU greatly
facilitates the synthetic circuit of sumoylation and that the
idea of simply fusing the Aos1 and Uba2 subunits would be
neat for the E. coli expression/modi¢cation system described
below.
3.3. Biosynthesis of sumoylated RanGAP1-C2 in E. coli
To produce sumoylated recombinant proteins through a
biosynthetic pathway in E. coli, we next constructed a binary
vector system by modifying pGEX and pACYC plasmids. The
generated plasmids were designated p-I and p-II (Fig. 3A).
Due to the plasmid compatibility, E. coli can be co-trans-
formed with p-I and p-II to produce four foreign proteins,
E1 (AU), E2 (Ubc9), SUMO-1 and RanGAP1-C2. In the
p-I plasmid, AU is designed to be expressed as a GST fusion
protein. Although the fusion of the GST moiety to the N-
terminus at the AU protein appears to reduce its E1 activity
(data not shown), we thought it is convenient to monitor and
purify the expressed E1 protein in E. coli.
After E. coli BL21(DE3) was transformed with p-I and
p-II(SUMO-1 wt+RanGAP1-C2 wt) plasmids, the bacteria
were cultivated in the presence of IPTG and the total lysate
was analyzed by immunoblotting (Fig. 3B). As expected, we
found the expression of four foreign proteins as well as su-
moylated RanGAP1-C2 around 40 kDa, suggesting that the
SUMO conjugation pathway was reconstituted in E. coli.
Comparing the band intensities between free SUMO-1 and
the 40 kDa conjugated bands, V90% of the total expressed
SUMO-1 was subjected to sumoylation of RanGAP1-C2 (lane
1). On the other hand, V90% of the total expressed Ran-
GAP1-C2 appeared to be sumoylated (lane 9). Importantly,
we hardly detected other proteins modi¢ed by SUMO-1 in the
total bacterial lysate. These results indicate that the exoge-
nously expressed SUMO-1 is selectively conjugated to the
exogenously expressed RanGAP1-C2, but not to the bacterial
host proteins (lane 1).
The sumoylated RanGAP1-C2 generated in the E. coli ex-
pression/modi¢cation system could be puri¢ed using Ni2þ
beads (Fig. 3C). Using puri¢ed bovine serum albumin as a
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Fig. 2. AU is less active than the authentic Aos1/Uba2 heterodimer.
A: Puri¢cation of recombinant AU protein. Recombinant GST-
Aos1, (His)6-Uba2 and (His)6-AU proteins were incubated with
thrombin to remove GST and (His)6 moieties from the fusion pro-
teins. The puri¢ed proteins (0.2 Wg/lane) were analyzed on a 12%
SDS^PAGE gel followed by Coomassie blue staining. The positions
of recombinant Aos1 (lane 1), Uba2 (lane 1) and AU (lane 2) pro-
teins are indicated by arrow, arrowhead and line, respectively. Pro-
tein size markers are indicated on the left. B: AU sumoylates Ran-
GAP1-C2 less e⁄ciently than Aos1/Uba2 heterodimer does.
Di¡erent amounts of either AU or Aos1/Uba2 complex as indicated
were incubated with 0.1 Wg of Ubc9, 0.1 Wg of SUMO-1 and 0.1 Wg
of RanGAP1-C2 at 30‡C for 10 min in the sumoylation bu¡er. The
reaction mixture was then analyzed by immunoblotting using anti-
T7 tag antibody to detect non-modi¢ed (arrowhead) and sumoylated
(arrow) RanGAP1-C2 (shown in the inset). The signals of modi¢ed
proteins in the each lane were quanti¢ed using the image analyzing
system. A. U. represents arbitrary unit. C: Comparison of time-de-
pendent sumoylation mediated by AU versus Aos1/Uba2 hetero-
dimer. 0.01 Wg of either AU or Aos1/Uba2 complex was incubated
with 0.1 Wg of Ubc9, 0.1 Wg of SUMO-1 and 0.1 Wg of RanGAP1-
C2 at 30‡C for 0, 0.5, 1, 3, 4, 6, 8, 10, 12, 15, 20, 30 or 60 min in
the sumoylation bu¡er. The reaction mixture was then analyzed by
immunoblotting using anti-T7 tag antibody to detect non-modi¢ed
(arrowhead) and sumoylated (arrow) RanGAP1-C2. The signals of
modi¢ed proteins in the each lane were quanti¢ed using the image
analyzing system. A. U. represents arbitrary unit.
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control, we determined the amount of puri¢ed sumoylated
RanGAP1-C2 on a Coomassie blue-stained gel and estimated
that the yield was approximately 2.5 mg from a 1 l culture
(data not shown). It should be noted that Ubc9 was co-puri-
¢ed with sumoylated RanGAP1-C2 (Fig. 3C, lanes 1 and 13),
suggesting that the functional interaction between these pro-
teins was stably maintained in E. coli [10,11]. Importantly, we
failed to detect the 40 kDa band in lysate from the bacteria
expressing mutant SUMO-1 and/or mutant RanGAP1-C2
(Fig. 3B,C, lanes 2^4, 10^12), indicating that sumoylation in
E. coli occurred speci¢cally via an isopeptide bond between
Lys517 of RanGAP1 and glycine at the C-terminus of
SUMO-1 as predicted from in vivo studies [6,10,11].
3.4. Biosynthesis of sumoylated p53, PML and RanBP2-IR in
E. coli
To demonstrate that the binary vector system is broadly
applicable, we examined several proteins that have previously
been shown to be sumoylated in vivo and/or in vitro, includ-
ing the suppressor oncogene product, p53 [12,13], the nuclear
domain protein, PML [14], and the cytoplasmic ¢lament com-
ponent of the nuclear pore complex, RanBP2 [6,15]. As shown
in Fig. 4, (His)6-T7-p53, (His)6-T7-PML and (His)6-T7-
RanBP2-IR were e⁄ciently sumoylated in the E. coli expres-
sion/modi¢cation system, indicating that the system is appli-
cable to a wide variety of SUMO-1 acceptor proteins. The
yields of sumoylated p53, PML and RanBP2-IR were approx-
imately 40 Wg, 5.0 Wg and 500 Wg from 1 l of culture, respec-
tively, suggesting that the e⁄ciency of this system varies with
substrate proteins. It should be noted that the SUMO-1 moi-
ety of all the sumoylated recombinant proteins described
above could be released by a SUMO-speci¢c isopeptidase
(Y. Uchimura, T. Nishida, and H. Saitoh, unpublished re-
sults), indicating that the conjugations were each mediated
by an isopeptide-bond.
4. Discussion
Although an in vitro conjugation reaction is convenient for
producing sumoylated recombinant proteins, it may prove
di⁄cult to sumoylate proteins on a large scale without a large
amount of e¡ort. In this report, we have demonstrated a
novel and versatile system that can produce large amounts
of functional sumoylated proteins of interest. To our knowl-
edge, this study is the ¢rst demonstration that the introduc-
tion of the SUMO-1 conjugation system has little con£ict with
endogenous metabolic pathways and allows the production of
large amounts of sumoylated proteins in E. coli.
In the process of developing this system, we revealed AU, a
linear fusion product of Aos1 and Uba2, functions as the
SUMO-E1 in vitro. This observation indicates that the hetero-
dimeric structure of the SUMO-E1 enzyme is not essential
for the E1 enzymatic activity per se. However, it implies
that the Aos1/Uba2 heterodimer lends itself to several modes
of regulation that would not be applicable for linear-type E1.
It will be interesting to test whether overexpression of AU in
mammalian cells causes uncontrolled sumoylation of cellular
proteins, then in£uences the cell cycle progression and/or cel-
lular di¡erentiation.
Currently, we have succeeded in producing SUMO-2-con-
jugated proteins in E. coli using a similarly designed system
(manuscript in preparation). We therefore believe that other
isopeptide-bond-mediated protein^protein conjugation sys-
tems such as ubiquitinylation [16], neddylation [17], and
Apg12 conjugation [18] could be introduced into E. coli by
the binary vector system and that proteins modi¢ed by these
respective modi¢ers could be produced in large amounts.
However, it remains to be elucidated whether the protease(s)
that cleaves the isopeptide bonds of ubiquitin, Nedd8, or
Apg12 with the acceptor proteins is present in E. coli. If
such an isopeptidase(s) is present in E. coli, then possible
Fig. 4. RanBP2-IR, PML and p53 can be modi¢ed by SUMO-1 in
E. coli. Total lysates from each bacterial culture were incubated
with Ni2þ beads and the proteins bound to the beads were analyzed
by SDS^PAGE followed by immunoblotting analyses using anti-T7
(lanes 1, 2, 5, 6, 9 and 10) or anti-SUMO-1 (lanes 3, 4, 7, 8, 11 and
12) antibodies. Lanes 1 and 3: p-I plus p-II(SUMO-1 wt+(His)6-T7-
tagged p53), lanes 2 and 4: p-I plus p-II(SUMO-1G96+(His)6-T7-
tagged p53), lanes 5 and 7: p-I plus p-II(SUMO-1 wt+(His)6-T7-
tagged PML), lanes 6 and 8: p-I plus p-II(SUMO-1G96+(His)6-T7-
tagged PML), lanes 9 and 11: p-I plus p-II(SUMO-1 wt+(His)6-T7-
tagged RanBP2-IR), and lanes 10 and 11: p-I plus p-II(SUMO-
1G96+(His)6-T7-tagged RanBP2-IR). Arrowheads indicate the posi-
tions of non-modi¢ed (His)6-T7-p53, (His)6-T7-PML and (His)6-T7-
RanBP2-IR, respectively.
6
Fig. 3. Production of sumoylated RanGAP1-C2 in E. coli. A: Structures of the p-I(AU+Ubc9) and p-II(SUMO-1 wt+RanGAP1-C2 wt) plas-
mids. B: Sumoylation of RanGAP1-C2 at lysine 517 in E. coli. E. coli harboring the p-I and p-II plasmids carrying the wild-type and/or mu-
tant SUMO-1/RanGAP1-C2 as indicated was cultured in the presence of IPTG. The total lysate was separated by 5^20% SDS^PAGE followed
by immunoblotting analyses with anti-SUMO-1 (lanes 1^8), anti-(His)6 (lanes 9^12), anti-GST (lanes 13^16), or anti-Ubc9 (lanes 17^20) anti-
bodies. Anti-(His)6 and anti-GST antibodies detected the expressed recombinant RanGAP1-C2 and GST-AU, respectively. Lanes 5^8 are lon-
ger-exposed images of lanes 1^4. Arrows indicate the position of sumoylated RanGAP1-C2. The line shows the position of non-modi¢ed Ran-
GAP1-C2. Arrowheads represent the position of free SUMO-1. C: Expression and puri¢cation of sumoylated RanGAP1-C2. The total lysates
from bacteria harboring the plasmids as in B were incubated with Ni2þ beads and the proteins associated with the beads were analyzed by
5^20% SDS^PAGE followed by Coomassie blue staining (lanes 1^4). The bound proteins were also analyzed by immunoblotting using anti-
(His)6 (lanes 5^8), anti-SUMO-1 (lanes 9^12), or anti-Ubc9 (lanes 13^16) antibodies. Arrows indicate the position of sumoylated RanGAP1-C2.
Thin lines show the position of non-modi¢ed RanGAP1-C2. Arrowheads represent the position of Ubc9.
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reduction of the yield of the modi¢ed proteins would have to
be considered.
It is obvious that sumoylation is important in controlling
protein’s interaction, stability and activity in eukaryotic cells
and we are just starting to appreciate the SUMO-1 ‘code’. We
believe that the E. coli expression/modi¢cation system de-
scribed here will contribute to determining the complexity of
the code, that is, the number of distinct sumoylated states that
can be speci¢ed.
It would be interesting to determine the structures of su-
moylated proteins using either X-ray crystallography or nu-
clear magnetic resonance spectroscopy. We are also interested
in generating antibodies that could speci¢cally discriminate
modi¢ed from non-modi¢ed proteins in vivo using sumo-
ylated recombinant proteins either as immunogens themselves
or as proteins for screening.
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